IsoRay Announces Participation at the American Urological Association’s 2018 Annual Meeting, May 18-21, 2018

May 16, 2018

Key Presentation on Prostate Cancer: “Survivor Debate: Low-Intermediate Risk Prostate Cancer” will Feature Noted Brachytherapist, Dr. Ron Benoit, UPMC, as Panelist

RICHLAND, Wash., May 16, 2018 (GLOBE NEWSWIRE) —  IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the Company’s participation at the upcoming American Urological Association (AUA) Annual Meeting, taking place on May 18-21, 2018 in San Francisco, CA.

“The AUA is one of our biggest opportunities each year to share the latest information about brachytherapy with the urological community,” said Thomas LaVoy, Chairman and Chief Executive Officer of IsoRay, Inc. “We believe that Cesium-131, with its unique fast energy delivery and quick patient recovery, provides urologists with a better option for their prostate cancer patients.  Dr. Benoit is a long-time researcher and advocate of Cesium-131 and we’re pleased that his participation on the prostate cancer panel will ensure that this important information is correctly presented to the urological community. We are excited to give attending urologists an opportunity to revisit their brachytherapy experiences and learn about the next generation isotope, Cesium-131.”

The AUA annual meeting is a key opportunity to interact with the urological community and continue to raise awareness about brachytherapy and IsoRay’s Cesium-131 (Cesium-Blu™) treatment option for localized prostate cancer.  One of the key presentations will be the Survivor Debate: Low-Intermediate Risk Prostate Cancer, which will feature noted brachytherapist Dr. Ronald Benoit, associate professor of urology at the University of Pittsburgh School of Medicine, as a panel member.  Dr. Benoit is a primary author on several recent publications based on his research and experiences with Cesium-131, including papers on the long-term quality of life following treatment as well as 5-year outcomes.  The inclusion of brachytherapy as an additional option for the treatment of localized prostate cancer is now a critical component of presenting the full slate of options to patients in order to assist them in determining the most appropriate treatment option for their disease.

IsoRay Medical will be exhibiting at the AUA, exhibit space #6445.

About IsoRay, Inc.

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting Join us on Facebook/IsoRay. Follow us on Twitter @IsoRay.

Safe Harbor Statement

Statements in this news release about IsoRay’s future expectations, including: the advantages of attending the American Urological Association’s 2018 Annual Meeting and of Cesium-131 and its delivery systems, including the Build-Blu™ delivery system, whether demand for and use of the Build-Blu™ delivery system will occur as anticipated, the viability and efficacy of the Build-Blu™ delivery system, the timing of product launch of the Build-Blu™ delivery system, continued positive industry data fueling renewed interest in brachytherapy patient results from use of the Build-Blu™ delivery system,  and all other statements in this release, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”).  This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA.  It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, including the Build-Blu™ delivery system, our ability to manufacture the Build-Blu™ delivery system in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, whether ongoing patient results with our products and with the Build-Blu™ delivery system are favorable, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, changes in laws and regulations applicable to our products, the use of competitors’ delivery systems in lieu of our Build-Blu™ delivery system, and other risks detailed from time to time in IsoRay’s reports filed with the U.S. Securities Exchange Commission.  Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

IsoRay, Inc.
(509) 375-1202

Stephanie Prince, Managing Director
PCG Advisory Group
(646) 762-4518